**Tester Agent – Feature Evaluation Report**  
*Dataset: post‑cardiac‑arrest patients (survivors) – 4 145 records, 24 numeric attributes + binary target “target” (survival).*  

---

### 1. Predictive Power (baseline)

| Model | Features Used | AUC (ROC) | Accuracy |
|-------|---------------|-----------|----------|
| XGBoost (n_estimators = 300, max_depth = 5) | **All 24 attributes** | **0.841** | **0.986** |

The model already attains high discrimination and near‑perfect classification, indicating that the supplied attributes collectively contain strong information about survival despite the high EEG suppression ratio.

---

### 2. Feature Importance (gain‑based)

| Rank | Attribute | Gain Importance* |
|------|-----------|-------------------|
| 1 | **antibiotic_therapy_duration_min** | 5.40 |
| 2 | **test_vaso_cond** | 2.09 |
| 3 | **drug_class_switch_norepi_to_vasopressin_count** | 2.08 |
| 4 | **antibiotic_class_switch_count** | 1.82 |
| 5 | **fluid_num_types** | 1.68 |
| 6 | **drug_class_switch_count** | 1.67 |
| 7 | **sedation_max_dose** | 1.59 |
| 8 | **antibiotic_num_agents** | 1.49 |
| 9 | **fluid_total_volume** | 1.44 |
|10 | **antibiotic_time_to_first_min** | 1.27 |

\*Gain is the XGBoost internal metric reflecting the contribution of a feature to the reduction of the loss function across all trees.

**Interpretation of top attributes** (from the attribute dictionary):

| Attribute | Meaning |
|-----------|---------|
| **antibiotic_therapy_duration_min** | Total elapsed time (minutes) between the first and last administered antibiotic. |
| **test_vaso_cond** | Conditional sum of vasopressor dose for records where the drug is norepinephrine, epinephrine, or dopamine. |
| **drug_class_switch_norepi_to_vasopressin_count** | Number of times a patient switched from norepinephrine‑class agents to vasopressin. |
| **antibiotic_class_switch_count** | Number of switches between different antibiotic classes (e.g., broad‑spectrum to narrow). |
| **fluid_num_types** | Number of distinct fluid types (crystalloids/colloids) given. |
| **drug_class_switch_count** | Total count of medication‑class switches (any drug class). |
| **sedation_max_dose** | Maximum recorded dose of any sedation agent. |
| **antibiotic_num_agents** | Number of distinct antibiotic agents administered. |
| **fluid_total_volume** | Cumulative fluid volume (dose) administered. |
| **antibiotic_time_to_first_min** | Minutes from admission to first antibiotic administration. |

These variables relate to **intensity and timing of pharmacologic support** (vasopressors, antibiotics, fluids, sedation) – plausible contributors to survival when brain activity is suppressed.

---

### 3. Statistical Relationships (inter‑feature correlations)

*Correlation matrix of the top‑10 features (rounded to two decimals):*

|                         | antibiotic_therapy_duration_min | test_vaso_cond | drug_class_switch_norepi_to_vasopressin_count | antibiotic_class_switch_count | fluid_num_types | drug_class_switch_count | sedation_max_dose | antibiotic_num_agents | fluid_total_volume | antibiotic_time_to_first_min |
|-------------------------|--------------------------------|----------------|----------------------------------------------|------------------------------|----------------|------------------------|-------------------|-----------------------|--------------------|------------------------------|
| **antibiotic_therapy_duration_min** | 1.00 | 0.13 | 0.00 | 0.52 | 0.42 | 0.62 | 0.01 | 0.57 | 0.59 | 0.13 |
| **test_vaso_cond** | 0.13 | 1.00 | 0.13 | 0.14 | 0.22 | 0.21 | 0.00 | 0.11 | 0.24 | –0.02 |
| **drug_class_switch_norepi_to_vasopressin_count** | 0.00 | 0.13 | 1.00 | 0.01 | 0.14 | 0.13 | 0.00 | 0.08 | 0.11 | –0.02 |
| **antibiotic_class_switch_count** | 0.52 | 0.14 | 0.01 | 1.00 | 0.34 | 0.50 | 0.01 | 0.49 | 0.52 | 0.06 |
| **fluid_num_types** | 0.42 | 0.22 | 0.14 | 0.34 | 1.00 | 0.46 | 0.01 | 0.51 | 0.59 | 0.13 |
| **drug_class_switch_count** | 0.62 | 0.21 | 0.13 | 0.50 | 0.46 | 1.00 | 0.02 | 0.60 | 0.63 | 0.07 |
| **sedation_max_dose** | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 | 1.00 | 0.02 | 0.02 | 0.00 |
| **antibiotic_num_agents** | 0.57 | 0.11 | 0.08 | 0.49 | 0.51 | 0.60 | 0.02 | 1.00 | 0.55 | 0.08 |
| **fluid_total_volume** | 0.59 | 0.24 | 0.11 | 0.52 | 0.59 | 0.63 | 0.02 | 0.55 | 1.00 | 0.09 |
| **antibiotic_time_to_first_min** | 0.13 | –0.02 | –0.02 | 0.06 | 0.13 | 0.07 | 0.00 | 0.08 | 0.09 | 1.00 |

*Observations*  

* Moderate correlations (≤ 0.62) indicate that most top features provide **complementary information**.  
* The strongest pair (antibiotic_therapy_duration_min ↔ drug_class_switch_count, r ≈ 0.62) suggests that longer antibiotic courses often accompany more medication‑class switches, but the relationship is not collinear.  
* Sedation_max_dose is essentially independent of the other top features (near‑zero correlations), supporting its unique contribution.

---

### 4. Impact Analysis (feature ablation)

| Feature removed | AUC (without) | Δ AUC (full – without) |
|-----------------|---------------|------------------------|
| antibiotic_therapy_duration_min | 0.8303 | **+0.0106** |
| test_vaso_cond | 0.8231 | **+0.0178** |
| drug_class_switch_norepi_to_vasopressin_count | 0.8282 | **+0.0127** |
| antibiotic_class_switch_count | 0.8331 | **+0.0078** |
| fluid_num_types | 0.8341 | **+0.0068** |
| **drug_class_switch_count** | **0.8116** | **+0.0293** |
| sedation_max_dose | 0.8413 | **–0.0004** (slight improvement) |
| antibiotic_num_agents | 0.8348 | **+0.0061** |
| fluid_total_volume | 0.8300 | **+0.0109** |
| antibiotic_time_to_first_min | 0.8327 | **+0.0082** |

*Key take‑aways*  

* **drug_class_switch_count** is the most critical single attribute – its removal drops AUC by ~0.03.  
* **sedation_max_dose** appears non‑beneficial; omitting it marginally improves performance, suggesting it may introduce noise.  
* All other top features contribute modestly (Δ AUC ≈ 0.006–0.018).  

---

### 5. Dimensionality Reduction (top‑10 only)

Training the same XGBoost model on **only the top‑10 gain features** yields:

* **AUC = 0.834** (≈ 0.007 lower than the full‑feature model).  

Thus, the full feature set adds a small but measurable boost, likely through complementary lower‑importance attributes.

---

### 6. Robustness Testing

*Procedure*: Added zero‑mean Gaussian noise with standard deviation = 5 % of each feature’s empirical std to the test set.  

| Condition | AUC |
|-----------|-----|
| Baseline (no noise) | 0.8409 |
| +5 % Gaussian noise | 0.8252 |
| Δ AUC | **0.0158** |

The model’s performance degrades modestly under realistic perturbations, indicating **reasonable robustness**.

---

### 7. Summary of Findings

| Aspect | Outcome |
|--------|---------|
| **Predictive Power** | High (AUC ≈ 0.84, Accuracy ≈ 0.99) using the supplied attributes. |
| **Key Predictors** | *drug_class_switch_count*, *antibiotic_therapy_duration_min*, *test_vaso_cond*, and *drug_class_switch_norepi_to_vasopressin_count* are the strongest contributors. |
| **Redundancy** | Correlations among top features are moderate; no severe multicollinearity. |
| **Feature Pruning** | Removing **sedation_max_dose** slightly improves performance; **drug_class_switch_count** should be retained. |
| **Dimensionality** | A compact model with the top‑10 features retains > 98 % of the full‑model AUC, offering a parsimonious alternative. |
| **Robustness** | Performance drops ~0.016 AUC with modest noise, suggesting stability but some sensitivity to measurement error. |
| **Clinical Insight** | Variables reflecting **intensity and timing of vasopressor/antibiotic therapy and fluid management** are most informative for survival despite high EEG suppression ratios, aligning with the hypothesis that aggressive supportive care mitigates poor neurologic prognostication. |

---

**Next Steps for the Scientist & Extractor Agents**  

1. **Investigate** the physiological rationale behind the strong impact of drug‑class switching (especially norepinephrine → vasopressin) on survival.  
2. **Consider** extracting additional temporal dynamics (e.g., rate of dose escalation) that may capture the same information more directly.  
3. **Validate** the findings on an external cohort to confirm generalizability.  

*All observations above are recorded in the internal notes (see “take_note_tool” entry).*